JPRN-UMIN000035622已完成2 期
A Multicenter Phase II study of Trastuzumab emtansine for non-small cell lung cancer positive for HER2 exon 20 insertion mutation. - PRECISION trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with an infection requiring systemic treatment 2.Patients with treatment history of HER2 inhibitors 3.History of hypersensitivity of grade 3 or more to additive substance (sodium succinate, sucrose, polysorbate 20) of that of severe hypersensitivity to other drugs 4.Patients with clinically significant psychiatric disease or symptom that would interfere with participation in this study. 5.With driver mutation other than HER2 mutation (EGFR activating mutation, ALK fusion gene, ROS1 fusion gene, BRAF V600E, RET fusion gene, MET exon 14 skip mutation, NTRK fusion gene) 6.Patients with symptomatic brain metastases 7.Patients with carcinomatous meningitis 8.Patients with active double cancer 9.Patients with poorly controlled hypertension or diabetes mellitus 10.Patients with clinically meaningful heart diseases including 1)New York Heart Association(NYHA)class II or more or heart disorder with Grade 3 or more assessed by CTCAE v5.0 2)Patients with congestive heart failure or medication-needed ventricular arrythmia within 6 months 11.Patients with clinically meaningful coronary artery disease (unstable angina, myocardial infarct) within 6 months 12. Patients with positive for hepatitis B surface (HBs) antigen or positive hepatitis C virus (HCV) antibody 13. Patients with distinct interstitial pneumonitis or pulmonary fibrosis based on chest CT 14. Pregnant or lactating females. Females of child-bearing potential with the positive result of the urine pregnancy test that was carried out within 14 days before enrollment
研究者
相似试验
撤回
不适用
Ramucirumab, Paclitaxel, and Trastuzumab biosimilar combination treatment in HER2 positive metastatic gastric cancer patientsNeoplasmsKCT0003638Chonbuk National University Hospital53
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28
进行中（未招募）
1 期
A study in patients with HER2-positive breast cancer that has spread and has not responded to one course of anti-cancer therapy.HER2-positive metastatic breast cancerMedDRA version: 14.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001628-37-NOF. Hoffmann-La Roche Ltd2,003
进行中（未招募）
1 期
A study in patients with HER2-positive breast cancer that has spread and has not responded to one course of anti-cancer therapy.HER2 positive metastatic breast cancerMedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 100000004864EUCTR2012-001628-37-GRF. Hoffmann-La Roche Ltd2,003
进行中（未招募）
1 期
A study in patients with HER2-positive breast cancer that has spread and has not responded to one course of anti-cancer therapy.HER2 positive metastatic breast cancerMedDRA version: 15.0Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001628-37-ESF. Hoffmann-La Roche Ltd (representado en España por Roche Farma, S.A)1,000